Related Experiment Videos
A monoclonal antibody which identifies the autophosphorylation domain of autophosphorylating protein kinase 500
G Majumdar1, W E Jefferson, R K Sharma
1Section of Regulatory Biology, Cleveland Clinic Research Institute, Ohio 44195-5068.
Abstract:
Autophosphorylating protein kinase 500 is a serine protein kinase expressed progressively with the steps of cellular transformation, approaching levels from 50- to 100-fold in the terminal stages of malignancy. The enzyme possesses a sharply restricted range of substrates: itself and a ribosomal protein with a molecular weight of 31,000 (S6). We report here on the characterization of a monoclonal antibody directed against the autophosphorylation domain of AUT-PK 500. The specificity of the antibody is evidenced by blockage of the enzyme phosphorylation without interfering with the native S6 or synthetic octapeptide (S6-1) serine residue phosphorylations. This represents an important step in identifying a probe that can be used to explore the structure and potential function of AUT-PK 500 in cellular transformation.
Insights
Researchers developed a specific antibody targeting autophosphorylating protein kinase 500 (AUT-PK 500), a key enzyme in cellular transformation. This antibody can help study AUT-PK 500
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Autophosphorylating protein kinase 500 (AUT-PK 500) is a serine protein kinase.
- AUT-PK 500 expression increases during cellular transformation, with 50- to 100-fold elevation in advanced malignancy.
- The enzyme's substrates include itself and ribosomal protein S6.
Purpose of the Study:
- To characterize a monoclonal antibody against the autophosphorylation domain of AUT-PK 500.
- To develop a specific probe for investigating AUT-PK 500's role in cellular transformation.
Main Methods:
- Characterization of a monoclonal antibody.
- Assessing antibody specificity through phosphorylation assays.
- Testing antibody interference with AUT-PK 500, native S6, and synthetic octapeptide (S6-1) phosphorylations.
Main Results:
- A monoclonal antibody targeting the autophosphorylation domain of AUT-PK 500 was successfully characterized.
- The antibody specifically blocked AUT-PK 500 autophosphorylation.
- The antibody did not interfere with the phosphorylation of native S6 or the synthetic octapeptide S6-1.
Conclusions:
- The developed monoclonal antibody is specific for the autophosphorylation domain of AUT-PK 500.
- This antibody serves as a valuable tool for exploring the structure and function of AUT-PK 500 in cancer.
- Further research can utilize this probe to understand AUT-PK 500's involvement in cellular transformation and malignancy.